Capital Asset Advisory Services’s Genocea Biosciences, Inc. GNCA Stock Holding History

Capital Asset Advisory Services’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-11,766	Closed	-$15K	–	627
2022 Q1	$15K	Hold	11,766	–	–	﹤0.01%	463
2021 Q4	$14K	Hold	11,766	–	–	﹤0.01%	502
2021 Q3	$23K	Hold	11,766	–	–	﹤0.01%	545
2021 Q2	$28K	Buy	+11,766	New	+$28.4K	﹤0.01%	565
2021 Q1	–	Sell	-9,462	Closed	-$23K	–	1670
2020 Q4	$23K	Buy	+9,462	New	+$21.6K	﹤0.01%	829

Other funds holding GNCA

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

AICPI

ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

Capital Asset Advisory Services's GNCA Position: Q2 2022 in Review

Capital Asset Advisory Services sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2022, closing a stake of 11,766 shares — an estimated $15K sold.

Capital Asset Advisory Services first reported a position in GNCA in Q4 2020 and held it in 5 quarters. The position peaked at $28K in Q2 2021. 5 funds tracked by Wall St. Rank hold GNCA as of Q2 2022.

Capital Asset Advisory Services reported no remaining Genocea Biosciences, Inc. position as of Q2 2022 after selling out during the quarter.
Capital Asset Advisory Services sold 11,766 Genocea Biosciences, Inc. shares in Q2 2022, an estimated $15K.
Capital Asset Advisory Services first reported a position in Genocea Biosciences, Inc. in Q4 2020 and held it in 5 quarters.
Capital Asset Advisory Services's Genocea Biosciences, Inc. position peaked at $28K in Q2 2021.
5 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2022.

Based on Capital Asset Advisory Services's 13F filing for Q2 2022, filed 11 Aug 2022.